Zentalis Pharmaceuticals To Participate In The Oppenheimer Healthcare Life Sciences Conference


(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis, will participate in a webcast fireside chat at the Oppenheimer Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 12:40 p.m. ET.

Access to a live webcast of this event, as well as an archived recording, will be available under the“Events & Presentations” tab on the Investors & Media section of the Company's website .

About Zentalis Pharmaceuticals

Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company's lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors and hematologic malignancies. Azenosertib is being evaluated as a monotherapy and in combination across multiple clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. As part of its azenosertib clinical development program, the Company is exploring enrichment strategies targeting tumors of high genomic instability, such as Cyclin E1 positive tumors and homologous recombination deficient tumors. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in both New York and San Diego.

For more information, please visit . Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at .

Contact:

Carlo Tanzi, Ph.D.
Kendall Investor Relations
...


MENAFN13022024004107003653ID1107845698


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.